VitaDX launches today its first clinical trial VisioCyt 1. This multicentric study on 1300 patients aims to evaluate the diagnostic performances of the VisioCyt® test.
Thursday January 5th, 2017
Tuesday December 20th, 2016
VitaDX is one of the top 100 medical technology startups, according to Innovation Review magazine.
Wednesday November 23rd, 2016
VitaDX and EVOSCIENCES enter into a partnership to facilitate access to the equipment required for the implementation of the VisioCyt® solution.
Friday April 1st, 2016
Monday February 1st, 2016
Friday January 15th, 2016
Friday January 1st, 2016
Thursday October 1st, 2015
Tuesday September 1st, 2015
Jacques Le Bozec, former President of Vitalitec, takes over the chairmanship of the board of VitaDX
Monday June 1st, 2015
The SATT Paris-Saclay supports the VitaDX start-up to develop a promising new technique for early cancer diagnosis, resulting from joint research between the ONERA (French Aerospace Lab), CNRS (French Centre for Scientific Research), Paris Hospitals (AP-HP) and the University of South-Paris.